Hovione Launches Rapid Proof-of-Concept DPI Product Development Service
Hovione recently announced the launch of its Rapid Proof-of-Concept Study for the development of dry powder inhalation (DPI) products. Building on Hovione’s well-established DPI development capability, the new service simplifies the development of formulations, producing a proof-of-concept formulation of a client’s molecule in just a few weeks.
Hovione has simplified DPI product development, reduced complexity, and reduced the time required for completion by mastering, in concert, particle engineering, formulation technology, and inhaler design, the three disciplines vital to the development of a successful product. Unlike other CROs, Hovione has all of this expertise under one roof, eliminating the coordination issues clients often experience in having to use multiple CROs. The results of this are reduced coordination costs, shortened development timescales, and a streamlining of the development process.
“This new Rapid Proof-of-Concept service offers clients a low risk look at the feasibility of developing a DPI product and gives clients greater confidence about going into later stage development,” said Peter Villax, Hovione’s Vice President of Pharma & Innovation. “Clients of the new service don’t just get a report, they get their first DPI formulation.”
In a short period of time and for relatively little investment, a drug developer can acquire a DPI formulation, potentially adding significant value to an early stage out-licensing opportunity or helping a company move into a stronger position in funding negotiations with venture capitalists.
Hovione is an international company with over 50 years of experience in API development and compliant manufacture. With four FDA-inspected sites in the
Total Page Views: 1009
